Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fasinumab AI · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Auto-injector (AI) | EXPERIMENTAL | - |
| Prefilled syringe (PFS) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Fasinumab AI | DRUG | Self-administered with auto injector |
| Fasinumab PFS | DRUG | Prefilled syringe administered by study staff |
Key Inclusion Criteria: 1. A clinical diagnosis of Osteoarthritis (OA) of the knee or hip based on the American College of Rheumatology criteria with radiologic evidence of OA (K-L score ≥2 for the index joint) at the screening visit 2. Moderate-to-severe pain in the index joint defined as a WOMAC ...
Fasinumab AI is an investigational small molecule being developed for osteoarthritis, specifically for osteoarthritis of the knee. It is currently in Phase 1 clinical development and is not approved for any use.
Fasinumab AI is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker REGN. The drug is currently in Phase 1 clinical trials.
Fasinumab AI is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
Fasinumab AI has one completed Phase 1 clinical trial, identified as NCT03491904. This trial assessed patients' ability to self-administer the drug and enrolled 100 participants with osteoarthritis of the knee or hip in the United States.
Fasinumab AI is a distinct drug candidate from fasinumab. While both are being developed by Regeneron, Fasinumab AI is a small molecule in Phase 1 development for knee osteoarthritis, whereas fasinumab is a different investigational product.